目前国内免疫药物主要有PD-1单抗和PD-L1单抗两大类。大家可能觉得，这两种药物其实是针对同一免疫通路的两个端点，机制上似乎是一致的。其实不然，两者之间存在着一定的区别，无论是在药物设计、作用机制到临床疗效，甚至耐药处理上都有不同之处。今天就全面给 ...

【导读】免疫检查点阻断（ICB）疗法已成为多种晚期癌症的新治疗范式，但由于低响应率，其广泛的临床应用受到了阻碍。在这项研究中，团队采用了一种基于肽的、仿生的、自组装策略，制造了一种纳米颗粒TPM1，用于结合肿瘤细胞表面的PD-L1。2024年11月9 ...

See now: Merck says trial of combination treatment for colon cancer failed to meet main goal PD-L1 is found in healthy cells ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

Radiopharm Theranostics has received approval from the Australian Ethics Committee for the inclusion of more tumour types ...

BNT327 and ivonescimab are designed to unleash T cells against tumors, like standard checkpoint inhibitors do, while also ...

An expert explained how a patient’s own T cells can be extracted, manufactured and infused back into the body as a treatment ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...